04:21 , Dec 8, 2017 |  BC Week In Review  |  Company News

OncoQuest partners with Tesaro for Phase I/II ovarian cancer combo trial

In October, the OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) partnered with Tesaro Inc. (NASDAQ:TSRO) to conduct a Phase I/II combination trial of OncoQuest's oregovomab (OvaRex Mab, OvaRex) plus Tesaro's Zejula niraparib to treat...
23:32 , Sep 14, 2017 |  BC Week In Review  |  Clinical News

Quest PharmaTech begins Phase I/II of oregovomab for ovarian cancer

The OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) began a Phase I/II trial of oregovomab (OvaRex Mab, OvaRex) plus Hiltonol (Poly-ICLC) from Oncovir Inc. (Washington, D.C.) to treat recurrent ovarian cancer. The open-label, U.S....
21:01 , May 17, 2017 |  BC Week In Review  |  Clinical News

OncoQuest begins Phase Ib/IIa of oregovomab in ovarian cancer

Quest PharmaTech Inc. (TSX-V:QPT) subsidiary OncoQuest Inc. began the Phase Ib/IIa ORION-01 trial to evaluate oregovomab (OvaRex Mab, OvaRex) plus Opdivo nivolumab in about 32 patients with recurrent epithelial ovarian cancer who have progressed after...
20:43 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Oregovomab: Interim Ph IIb QPT-ORE-002 data

Quest’s OncoQuest Inc. subsidiary reported interim data from the open-label, U.S. and Italian Phase IIb QPT-ORE-002 trial in 97 patients with newly diagnosed, advanced epithelial ovarian, adnexal or peritoneal carcinoma showing that first-line treatment with...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

Vermillion sales and marketing update

Vermillion said its Aspira Inc. CLIA-certified reference lab is now operational. Aspira is providing diagnostic services, including OVA1 and Longitudinal CA 125 testing, to support clinical decision-making and advance personalized treatment plans. Aspira is located...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

Oregovomab: Completed Phase II enrollment

Quest completed enrollment of 80 patients in an open-label, U.S. and Italian Phase IIb trial evaluating 2 mg IV oregovomab plus carboplatin and paclitaxel vs. carboplatin and paclitaxel. Oregovomab is also in Phase II testing...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Oncovir, Quest Pharma deal

Quest and Oncovir partnered to evaluate Quest's oregovomab in combination with Oncovir's Hiltonol ( Poly-ICLC ) adjuvant in an Italian Phase II trial in 20 patients with ovarian cancer, which is expected to start in...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

AD Biotech, Quest Pharma deal

The companies formed a JV to develop immunotherapies for cancer. The companies will work together to co-develop products that combine their technologies. Quest PharmaTech said the deal gives it access to AD Biotech's antibody, protein...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Financial News

Quest Pharma proposes private placement

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta   Business: Dermatology, Cancer, Diagnostic   Date announced: 6/5/12   Type: Private placement   To be raised: Up to C$8 million ($7.7 million)   Shares: 15 million   Price...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

Paclical micellular paclitaxel: Completed Phase III enrollment

Oasmia completed enrollment of 650 patients in an open-label, European Phase III trial comparing 250 mg/m 2 Paclical given as a 1-hour infusion plus carboplatin on day 1 of each 21-day cycle vs. paclitaxel plus...